Jining

Researchers are evaluating the effectiveness and safety of B001 injection in patients who have neuromyelitis optica spectrum disorder NMOSD and test positive for aquaporin-4 antibodies. This condition involves recurrent attacks affecting the nervous system. The study is a multicenter, randomized, double-blind, placebo-controlled trial conducted in phases II and III to understand how well B001 works and how safe it is for these patients. Participants will receive intravenous doses of either B001 or a placebo on Day 1 and Day 15 during the randomized controlled period. The study includes two groups one receiving B001 injections and the other receiving placebo injections matching B001s schedule. The trial will extend over several years, monitoring patients closely for disease relapse and treatment side effects. During the study, participants will be regularly assessed for the time to their first NMOSD attack, changes in disability status, vision acuity, and opticospinal function. Researchers will also observe the annual relapse rate and document any adverse events. The trial includes safety monitoring for about three years to ensure comprehensive data collection on treatment impact and participant health.

Researchers are evaluating the effectiveness and safety of an investigational drug called BNT323 also known as DB-1303 compared with standard chemotherapy in women with recurrent endometrial cancer. The study includes two groups based on the level of HER2 protein in the tumor Cohort 1 with HER2 levels 1 or 2 who have been previously treated with immune checkpoint inhibitors, and Cohort 2 with HER2 level 3. The study aims to understand how well BNT323 or chemotherapy controls cancer progression and how the drug affects patients immune response and quality of life. Participants in Cohort 1 will be randomly assigned to receive either BNT323 or chemotherapy drugs such as doxorubicin, paclitaxel, or docetaxel. In Cohort 2, participants will receive BNT323 alone. Treatments are given intravenously and continue until the cancer progresses, unacceptable side effects occur, or consent is withdrawn. The study includes screening, treatment, safety follow-up, efficacy follow-up, and a long-term survival follow-up lasting up to about 53 months. During the study, participants will undergo regular assessments including tumor evaluations, safety monitoring, and quality of life questionnaires. Researchers will measure progression-free survival in Cohort 1 and tumor response rate in Cohort 2. Safety is monitored by tracking adverse effects and drug levels in the body. Participants can expect to be followed for up to 53 months after treatment to assess long-term outcomes and survival.

Researchers are evaluating TQB6411 injection, an antibody-conjugated drug that targets EGFR and c-Met proteins on tumor cells, in people with advanced malignant tumors. The study aims to assess how well patients tolerate the treatment, understand how the drug moves through the body, and observe early signs of its effects. This phase I clinical trial focuses on patients who have advanced cancer and have not responded to or cannot tolerate standard treatments. TQB6411 is given by intravenous injection every three weeks, with doses ranging from 0.8 mgkg to 8 mgkg at the start of each treatment cycle. The antibody in TQB6411 binds to cancer cells to block important growth signals, and then releases toxins inside the cells to cause DNA damage and cell death. The study includes a dose escalation stage to find the maximum tolerated dose and a dose expansion stage for specific tumor types such as advanced non-small cell lung cancer and metastatic colon cancer. Participants will have regular blood tests and tumor imaging to monitor safety and treatment effects for up to 24 months. Researchers will track dose-limiting toxicities, adverse events, drug levels in the blood, tumor response rates, and survival outcomes. Women of childbearing potential must use effective contraception during and for six months after the study. The trial includes careful monitoring to assess the bodys reaction to the drug and to gather information for future studies.

Researchers are evaluating IBI343 in people with locally advanced unresectable or metastatic solid tumors in a Phase IaIb, multicenter, open-label, first-in-human study. The trial aims to assess the safety, tolerability, how the drug moves through the body, and its effectiveness. The study includes participants from China, Australia, and the US and involves various stages to find the best dose and combination therapies. IBI343 is given intravenously and the study is divided into multiple parts. Phase Ia includes dose escalation, dose expansion, and dose optimization for monotherapy, with doses adjusted to balance benefits and risks. Phase Ib includes combination therapy with chemotherapy drugs like FOLFIRINOX or mFOLFOX, given every two to three weeks, with randomized groups to determine the optimal dose and safety. Participants will have regular visits for treatment and monitoring, including physical exams, laboratory tests, and imaging to measure tumor response using RECIST criteria. Safety is closely followed through adverse event tracking up to two years, along with assessments of drug levels in the body and immune response. The study also evaluates how tumor markers relate to treatment response, with total participation lasting up to two years.

Researchers are investigating the relationship between gut microbiota dysfunction and Alzheimers disease AD, focusing on how gut-derived short-chain fatty acids SCFAs may influence brain function through the gut microbiota-SCFAs-brain networks pathway. This observational study will explore differences in SCFAs among people across the AD spectrum, including cognitively normal individuals, those with subjective cognitive decline SCD, mild cognitive impairment MCI, and AD dementia. The project aims to clarify the interactions between gut microbiome, metabolites, and brain changes using high-throughput metabolomics and multi-modal MRI techniques. Participants will be grouped into four categories cognitively normal, SCD, MCI, and AD dementia. The study involves collecting multi-omics data, including gut microbiome analysis, metabolomics, and neuroimaging, to establish a diagnostic model for SCD due to preclinical AD using machine learning methods. The study spans five years, during which gut microbiome changes, SCFAs levels, and multi-omics biomarkers related to cognitive impairment conversion will be monitored. Participants will undergo cognitive tests and brain imaging scans, along with gut microbiome and metabolite sample collection. Researchers will assess the interaction mechanisms of the gut microbiota-SCFAs-brain networks over five years. The study includes both healthy volunteers and patients aged 60 to 80. Outcome measures focus on changes in gut microbiome, SCFAs, and biomarkers linked to cognitive decline, with long-term follow-up to better understand the disease progression and its early detection.

Researchers are evaluating the safety and tolerability of DB-1303BNT323 in adults with advanced or metastatic solid tumors that express HER2. This Phase 12a trial focuses on patients with tumors that are advanced, unresectable, recurrent, or metastatic and have limited or no standard treatment options. The study aims to identify the best dose and explore early signs of effectiveness in a variety of HER2-expressing cancers. The trial has two parts an initial dose-escalation phase using an accelerated titration followed by a classic 33 design to find the maximum tolerated dose MTD or recommended Phase 2 dose RP2D, and a dose-expansion phase to further assess safety, tolerability, and potential effects at the established dose. Participants receive DB-1303BNT323 by intravenous infusion once every three weeks Q3W at various dose levels. Some groups are randomized to receive different dose levels or combinations with other drugs like Pertuzumab, Ritonavir, or Itraconazole to study drug interactions and responses. During the study, participants will have regular assessments including monitoring for dose-limiting toxicities, adverse events, and serious adverse events using standard criteria up to about one year after treatment. Researchers will also evaluate tumor responses using RECIST 1.1 criteria and collect pharmacokinetic and pharmacodynamic data. Other evaluations include heart function tests, organ function, and overall health status. The study duration varies per participant, with follow-up visits extending up to one year post-treatment to monitor safety and treatment effects.

Researchers are evaluating the effectiveness, safety, and immune response of HB0017 injection given in different dosing schedules for adults with moderate to severe plaque psoriasis. This randomized, double-blind phase 2 trial focuses on patients who have had chronic plaque psoriasis for at least six months and meet specific severity scores. The study aims to better understand how various doses and timing of HB0017 impact psoriasis symptoms. Participants will be assigned randomly to one of three groups receiving HB0017 at different doses and schedules a higher dose with a longer dosing interval 300mg every 12 weeks, a higher dose with a shorter dosing interval 300mg every 8 weeks, or a lower dose with the shortest dosing interval 150mg every 4 weeks. The trial is designed to compare these regimens to assess their effects on psoriasis severity and maintenance of response. During the study, participants will be monitored closely with assessments of skin improvement using the Psoriasis Area Severity Index PASI and Static Physician Global Assessment sPGA at week 12, with follow-up evaluations up to week 48 to track ongoing response. Safety and immune reactions will also be observed throughout. The total study duration spans from initial treatment to long-term follow-up, ensuring detailed evaluation of both short- and longer-term effects of the HB0017 regimens.

Researchers are evaluating the efficacy and safety of QL2106 injection compared to Tremfya in patients with moderate to severe plaque psoriasis. This Phase 3, multicenter, randomized, double-blind, parallel, and active-controlled study plans to enroll 318 participants to better understand treatment effects in this population. Participants will be randomly assigned in equal numbers to receive either QL2106 injection or Tremfya. Both treatments are given by subcutaneous injection at Week 0, Week 4, and then every 8 weeks. The recommended dose for both is 100 mg. This study uses a quadruple blinding method to maintain objectivity. Throughout the study, researchers will assess the proportion of patients achieving a 75% improvement in the Psoriasis Area and Severity Index PASI-75 at Week 16. Participants will be monitored for safety and treatment response during the trial. The study is expected to continue until February 2028, with participants involved in regular visits according to the treatment schedule for assessment and care.

Researchers are conducting a Phase I, open-label, multi-center clinical trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of the drug JSKN021 in adults with advanced malignant solid tumors. This first-in-human study focuses on patients whose tumors have progressed after standard treatments, who are intolerant to standard therapies, or who have no access to such treatments. The trial aims to identify the optimal biological dose and recommended dose for future studies. Participants will receive JSKN021 administered intravenously at selected dose levels according to the study protocol. The trial includes multiple dose escalation cohorts followed by dose optimization cohorts to assess different dosing regimens. The study is randomized and evaluates various doses over time, with treatment continued under medical supervision. Each participant will undergo treatment cycles and monitoring as specified in the protocol. Throughout the study, participants will be closely monitored for adverse events, dose-limiting toxicities, and overall safety up to 30 days after the last dose or until new anti-tumor treatment begins. Researchers will assess tumor responses, disease control, progression-free survival, and overall survival over a period of up to 24 months. Pharmacokinetic parameters such as drug concentration levels and clearance will also be measured. Study visits will include clinical assessments, laboratory tests, imaging, and questionnaires to track treatment effects and participant well-being.

Researchers are conducting an open-label, multicenter phase 1 study to evaluate SIM0505 in adults with advanced solid tumors. The study aims to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of SIM0505 in participants who have progressed after or are ineligible for standard treatments. This trial includes multiple advanced cancers such as platinum-resistant ovarian cancer, renal cell carcinoma, uterine serous carcinoma, and non-small cell lung cancer among others. Participants receive SIM0505 in cycles lasting 21 days each. The study has different phases including dose escalation, where multiple dose levels are explored to find the maximum tolerated dose, followed by dose optimization phases that evaluate 2 to 3 dose levels to determine the recommended dose and assess preliminary antitumor activity across specific cancer types. The dosing and evaluation are conducted sequentially across various cohorts. Throughout the trial, participants undergo regular assessments including evaluation of dose-limiting toxicities at the end of the first cycle, ongoing monitoring for adverse events during the dose escalation phase, and measurement of objective response rates during dose optimization. Eligibility requires measurable lesions and adequate organ function among other criteria. The study may involve tumor tissue sampling for biomarker testing and requires participants to adhere to contraception guidelines if applicable. The total duration varies based on dose escalation and optimization phases, with safety and activity monitored over extended periods.